Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 5

  • 373 clinical trials
  • 123 recruiting
  • 138 conditions
  • 27 countries

Conditions in this area

138 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome31Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Dry age-related macular degeneration16Rhinitis allergic16Diabetic retinal oedema13Dry eye12Age-related macular degeneration11Retinitis pigmentosa11Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Neuromyelitis optica spectrum disorder6+114

Clinical trials in Eye disorders

373 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

373 clinical trials

Neovascular age-related macular degeneration+1

Recruiting

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myopia

Recruiting

Study on Brimonidine Eye Drops to Prevent Myopia Progression in Children Aged 6 to 14 Years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Brimonidine Tartrate
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal

Graves' disease

Recruiting

Study on the Effects and Safety of Rilzabrutinib for Adults with Graves' Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Uveal melanoma

Recruiting

Study on Tebentafusp and Liver Radiotherapy for Patients with Metastatic Uveal Melanoma HLA A*02:01 Positive

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tebentafusp
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Stargardt's disease

Recruiting

Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, C-REGION
  • Sponsor:Splicebio S.L.

Giant cell arteritis

Recruiting

Study on the Effectiveness of Abatacept for Patients with Giant Cell Arteritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Trustees Of The University Of Pennsylvania

Polypoidal choroidal vasculopathy

Recruiting

Study on the Effects of Faricimab for Caucasian Patients with Polypoidal Choroidal Vasculopathy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:Association For Innovation And Biomedical Research On Light And Image

Uveal melanoma

Recruiting

Study of Tebentafusp for Patients with Metastatic Uveal Melanoma and Resectable Liver Metastasis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tebentafusp
  • Sponsor:Grupo Espanol Multidisciplinar De Melanoma

Graves' disease

Recruiting

Study on the Effectiveness and Safety of IMVT-1402 for Adults with Graves' Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Neovascular age-related macular degeneration

Recruiting

Study of Faricimab Treatment Given Every 24 Weeks in Patients with Age-Related Macular Degeneration

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

Immunoglobulin G4 related disease+3

Recruiting

Study of 18F-AlF-FAPI-74 PET/CT imaging compared to standard 18F-FDG PET/CT in patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Conjunctivitis allergic+3

Recruiting

Study on the Effectiveness and Safety of Mannan-Conjugated Allergoids for Treating Allergic Rhinitis/Rhinoconjunctivitis in Patients Allergic to House Dust Mites

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dermatophagoides pteronyssinus enriched allergoid, mannan-conjugated, polymerised
  • Sponsor:Inmunotek S.L.

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.